AST Asterias Biotherapeutics, Inc.

3.70
+0  (0%)
Previous Close 3.70
Open 3.70
Price To book 3.97
Market Cap 171.76M
Shares 46,422,000
Volume 247,549
Short Ratio 7.57
Av. Daily Volume 223,155

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 2017.
AST-VAC2
Non-small cell lung cancer (NSCLC)
Phase 1/2 six and nine-month data released January 24, 2017 from AIS-A 10 million-cell cohort. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017.
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 2b planned for 2018.
AST-VAC1
Acute myeloid leukemia (AML)

Latest News

  1. Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position
  2. ASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Financial Sta
  3. ASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
  4. Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
  5. Asterias Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study
  6. Asterias Announces Successful Commencement of Operations at New GMP Manufacturing Facility for AST-OPC1
  7. Current report No 1/2017
  8. The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
  9. ETFs with exposure to Asterias Biotherapeutics, Inc. : December 27, 2016
  10. Is HC2 Holdings Inc (HCHC) A Good Stock To Buy?
  11. ETFs with exposure to Asterias Biotherapeutics, Inc. : December 8, 2016
  12. ETFs with exposure to Asterias Biotherapeutics, Inc. : November 28, 2016
  13. Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016
  14. ASTERIAS BIOTHERAPEUTICS, INC. Financials
  15. ASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
  16. Ryan Chavez Appointed Chief Financial Officer of Asterias Biotherapeutics
  17. ASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
  18. Asterias Biotherapeutics Inc (AST) Stock Will Be A Monster Bull!
  19. ASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  20. Asterias Biotherapeutics Reports Third Quarter Results and Accelerating Enrollment of AST-OPC1 SCiStar Phase 1/2a Study